Canada’s Drug Agency Issues Recommendation To Reimburse Yorvipath (Palopegteriparatide Injection) With Conditions For Eligible Adults With Chronic Hypoparathyroidism
ASND•Canada’s drug agency issues reimbursement recommendation
Canada’s drug agency issues a recommendation to reimburse Yorvipath (palopegteriparatide injection) with conditions for eligible adults with chronic hypoparathyroidism.
Sept. 3 (Reuters) -
- Canada’s drug agency issues recommendation to reimburse Yorvipath (palopegteriparatide injection) with conditions for eligible adults with chronic hypoparathyroidism.
Source text: ID:nGNX8yjS2R
